Health X Platform Ltd · NSE:HEALTHX
Health X Platform — SastaSundar Ventures — Q2 FY18 Earnings Presentation
28 slides from Health X Platform's earnings presentation, November 2017
Slide 1: Earnings Update Q2/H1FY18
EARNINGS UPDATE Q2/H1FY18 SastaSundar.com (A Venture of SastaSundar Ventures Limited) 1
Slide 2: Company Overview
COMPANY OVERVIEW 2 2
Slide 3: SastaSundar: About Us
SASTASUNDAR : ABOUT US • “Sasta Sundar” is a famous Indian phrase which denotes consumer aspiration for “High Quality at Low Cost”. • We are building Digital Network of Healthcare managing efficient Pharma & Wellness products Supply Chain & connecting Doctors, Diagnostic Services, Healthcare Clinics
Slide 4: Company Snapshot
COMPANY SNAPSHOT H1FY18 Product Categories * Own • SastaSundar Ventures Limited (Previously known as Microsec Financial Brands Services Ltd) is a NSE and BSE listed company. OTC 2% 10% • SastaSundar.com started its operations in September, 2013 with a Prescribed Medicines mission to provide low cost
Slide 5: Business Overview
BUSINESS OVERVIEW The company is building a Digital Network of Healthcare managing efficient Pharma & Wellness products Supply Chain & connecting Doctors, Diagnostic Services, Healthcare Clinics and Health Information Services. The Network is designed for the following services: 1.Access to Genuine
Slide 6: Q2FY18 Earnings Update
Q2FY18 EARNINGS UPDATE 6 6
Slide 7: Financial Performance Q2/H1FY18 (Consolidated)
FINANCIAL PERFORMANCE Q2/H1FY18 (CONSOLIDATED) Q2FY18 Q1FY18 Q2FY17 H1FY18 H1FY17 Particulars (INR Mn) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) Revenue* 364.64 392.20 382.94 756.85 677.42 Expenses 388.31 439.01 411.93 827.33 769.63 EBIDTA (23.67) (46.81) (28.99) (70.48) (92.21) Fi
Slide 8: Financial Performance Q2/H1FY18 (Standalone)
FINANCIAL PERFORMANCE Q2/H1FY18 (STANDALONE) Q2FY18 Q1FY18 Q2FY17 H1FY18 H1FY17 Particulars (INR Mn) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) Revenue* 0.25 0.04 2.87 0.29 5.11 Expenses 5.09 4.17 4.51 9.27 9.81 EBIDTA (4.84) (4.13) (1.65) (8.98) (4.70) Depreciation 0.50 0.54 0.74 1
Slide 9: Financial Performance Q2/H1FY18 (Segmental)
FINANCIAL PERFORMANCE Q2/H1FY18 (SEGMENTAL) Particulars (INR Mn) Q2FY18 Q1FY18 Q2FY17 H1FY18 H1FY17 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) Segment Revenue Financial Services 37.00 59.17 73.34 96.18 110.60 Digital Pharmacy and Healthcare Store 321.09 324.91 303.79 645.99 556.49 (
Slide 10: Income Statement of Subsidiary SastaSundar.com
INCOME STATEMENT OF SUBSIDIARY SASTASUNDAR.COM Q2FY18 Q1FY18 H1FY18 FY17 Particulars (INR Mn) (Unaudited) (Unaudited) (Unaudited) (Audited) Total Revenue* 323.32 325.94 649.26 1,126.45 Total Expenses# 373.45 378.06 751.51 1,351.14 EBITDA (50.13) (52.12) (102.25) (224.69) Depreciation 7.49 7.97 15.46
Slide 11: Key Highlights
KEY HIGHLIGHTS 11 11
Slide 12: Business Update – SastaSundar
BUSINESS UPDATE – SASTASUNDAR 1.82 lacs orders 186 Healthbuddies 93% Customer in September covering 22 districts of Retention Ratio. 2017. West Bengal around 5.21 lakh registered households. 3.23 Lac Plus Android App Downloads Strong unit economics with gross With 4.35 Google App Ratings by margins
Slide 13: Business Update – GMV growth and EBITDA
BUSINESS UPDATE – SASTASUNDAR 1800 Year wise growth in GMV EBITDA as % of GMV 1600 1,530 10% 1400 0% 1200 849 -11% -15% Rs. In Millions 1000 -10% 881 800 -20% -28% 600 902 -30% 400 681* -42% 274 -40% 200 0 -50% FY 2015 FY 2016 FY 2017 H1FY18 FY15 FY16 FY17 H1FY18 *H1FY17 numbers #Growth in compariso
Slide 14: Business Update – Orders and Repeat Customers
BUSINESS UPDATE – SASTASUNDAR No. of Orders (Lakhs) Customer Repeat Orders (%) 20 16.86 92% 93% 88% 90% 15 10.62 78% 9.05 10 70% 5 2.98 0 50% FY 2015 FY 2016 FY 2017 H1FY18 FY15 FY16 FY17 H1FY18 No. of Customers < Rs. 1,000 Rs. 1,000 to Rs. 1,499 Rs. 1,500 to Rs. 2,999 We are fulfilling on an aver
Slide 15: Strategic Agreement with Rohto Pharmaceuticals
STRATEGIC AGREEMENT WITH ROHTO PHARMACEUTICALS • SastaSundar Healthbuddy Limited has executed a share subscription agreement with Rohto Pharmaceuticals Ltd. in May 2017. • Rohto Pharmaceuticals has subscribed 13% of share capital on a fully diluted basis for an aggregate investment of $5Mn in the co
Slide 16: Expanding Our Presence
EXPANDING OUR PRESENCE • After the successfully penetration in the state of West Bengal, the company Our Next Foray - Delhi has planned to expand its presence in Delhi. • The work in Delhi is going as per plan and the company is expecting to launch the services in Delhi in Q4-FY17-18. Market overvie
Slide 17: New Initiatives
NEW INITIATIVES Starting Diagnostic Services by setting up Central Lab in Kolkata supported with multiple Reference lab (Centres) under a separate 100% wholly owned Subsidiary – Genu Path Labs Ltd. This subsidiary will enable the Healthbuddy network to provide extension of service from pharmacy to p
Slide 18: New Initiatives - Retailershakti
NEW INTIATIVES - RETAILERSHAKTI • Retailer Shakti is a platform to empower neighbourhood retailers to be a part of an organised inventory, technology & finance system to provide competitive advantage to their customers in terms of wide range of products, price & experience. • It provides the widest
Slide 19: New Initiatives – Retailershakti Website
NEW INTIATIVES – RETAILERSHAKTI WEBSITE 19
Slide 20: New Initiatives – Retailershakti App
NEW INTIATIVES – RETAILERSHAKTI APP 20
Slide 21: Financial Overview
FINANCIAL OVERVIEW 21 21
Slide 22: Financial Performance FY17 (Standalone)
FINANCIAL PERFORMANCE FY17 (STANDALONE) FY17 FY16 Particulars (INR Mn) (Audited) (Audited) Revenue * 9.77 22.15 Expenses 18.00 20.27 EBIDTA (8.23) 1.88 Depreciation 2.74 3.39 Profit / (Loss) before tax & exceptional items Particulars (INR Mn) (10.97) (1.51) Exceptional Item 13.40 23.70 Profit / (Los
Slide 23: Financial Performance FY17 (Consolidated)
FINANCIAL PERFORMANCE FY17 (CONSOLIDATED) FY17 FY16 Particulars (INR Mn) (Audited) (Audited) Revenue* 1,370.25 889.92 Expenses 1,552.52 1,175.45 EBIDTA (182.27) (285.53) Finance Cost 28.09 10.02 Particulars (INR Mn) Depreciation 69.18 72.79 (Loss) before tax (279.54) (368.34) Provision for Tax 6.19
Slide 24: Financial Performance FY17 (Segmental)
FINANCIAL PERFORMANCE FY17 (SEGMENTAL) FY17 FY16 Particulars (INR Mn) (Audited) (Audited) Segment Revenue Financial Services 203.45 194.56 Digital Pharmacy and Healthcare Store 1124.84 661.94 (www.sastasundar.com) Other Segment* 0.51 5.89 Total 1,328.80 862.39 Segment Results (Profit/(loss) before U
Slide 25: Consolidated Balance Sheet
CONSOLIDATED BALANCE SHEET Sources of Funds (INR in Mn) H1FY18 FY17 FY16 Application of Funds (INR in Mn) H1FY18 FY17 FY16 Equity & Liabilities Assets Shareholder's Fund Fixed Assets 634.85 674.05 689.88 Share Capital 318.10 318.10 318.10 Goodwill on Consolidation 550.67 573.85 573.85 Reserves & Sur
Slide 26: Capital Market Data
CAPITAL MARKET DATA 200% Sastasundar Sensex Price Data (30th September, 2017) INR 150% Face Value 10 100% Market Price 81.0 50% 52 Week H/L (INR) 154.3/43.2 0% Market Cap (INR Mn) 2,577 -50% Equity Shares Outstanding (Mn) 31.81 1 Year Avg. trading Volume ('000) 44.35 Share Holding Pattern (30th Sept
Slide 27: Disclaimer
DISCLAIMER Sastasundar.com This presentation and the accompanying slides (the “Presentation”), which have been prepared by Sastasundar.com (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for an
Slide 28: Thank You
Thank You 28 Health & Happiness